JPH10508868A - TP−3/p80を標的とする癌の生物療法 - Google Patents
TP−3/p80を標的とする癌の生物療法Info
- Publication number
- JPH10508868A JPH10508868A JP8521737A JP52173796A JPH10508868A JP H10508868 A JPH10508868 A JP H10508868A JP 8521737 A JP8521737 A JP 8521737A JP 52173796 A JP52173796 A JP 52173796A JP H10508868 A JPH10508868 A JP H10508868A
- Authority
- JP
- Japan
- Prior art keywords
- pap
- biotherapeutic
- antibody
- agent
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.p80骨肉腫に対する担体と結合したアメリカヤマゴボウ抗ウイルス・タン パク質の細胞障害性有効量を含む生物療法剤。 2.担体が抗体または抗体断片である、請求項1の生物療法剤。 3.抗体がTP-1、TP-3またはその誘導体である、請求項2の生物療法剤。 4.アメリカヤマゴボウが化学的架橋結合により抗体と結合している、請求項 3の生物療法剤。 5.アメリカヤマゴボウの1−3分子が抗体の各分子と結合している、請求項2 の生物療法剤。 6.p80抗原を発現する癌患者に、p80抗原に対する担体に結合したアメリカ ヤマゴボウ抗ウイルス・タンパク質の細胞障害性有効量を含有する生物療法剤の 治療的有効量を非経口的に投与することを含む癌の処置のための治療方法。 7.癌が肉腫である、請求項6の方法。 8.肉腫が骨肉腫である、請求項7の方法。 9.生物療法剤が薬学的に許容される液体担体と併用して投与される、請求項 6の方法。 10.液体担体が等張塩類を含む、請求項9の製法。 11.生物療法剤が静脈に投与される、請求項9の方法。 12.担体が抗体または抗体断片である、請求項6の方法。 13.抗体がTP-1、TP-3またはその誘導体である、請求項12の方法。 14.抗体がTP-3またはその活性サブユニットである、請求項13の方法。 15.PAPの1−3分子がTP-3の各分子に結合している、請求項14の方法 。 16.TP-3-PAP量は約1−7日を越えて投与される0.025−1mg/kgである 、請求項14の方法。 17.生物療法剤の投与に抗腫瘍薬の有効量の非経口投与を伴う、請求項6の 方法。 18.抗腫瘍薬がドキソルビシン、メトトレキセート、エトポシド、アルキル 化剤またはプラチナ化合物からなる群より選ばれる、請求項17の方法。 19.抗腫瘍薬が薬学的に許容される担体と結合している、請求項18の方法 。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/372,608 US5690935A (en) | 1995-01-13 | 1995-01-13 | Biotherapy of cancer by targeting TP-3/P80 |
US08/372,608 | 1995-01-13 | ||
PCT/US1996/000104 WO1996021467A1 (en) | 1995-01-13 | 1996-01-11 | BIOTHERAPY OF CANCER BY TARGETING TP-3/p80 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10508868A true JPH10508868A (ja) | 1998-09-02 |
Family
ID=23468893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8521737A Ceased JPH10508868A (ja) | 1995-01-13 | 1996-01-11 | TP−3/p80を標的とする癌の生物療法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US5690935A (ja) |
EP (1) | EP0802799A1 (ja) |
JP (1) | JPH10508868A (ja) |
AU (1) | AU4652496A (ja) |
CA (1) | CA2209767A1 (ja) |
WO (1) | WO1996021467A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008111597A1 (ja) * | 2007-03-12 | 2008-09-18 | Chugai Seiyaku Kabushiki Kaisha | Hlaクラスiを認識する抗体を有効成分として含有する化学療法剤耐性癌治療剤、およびその利用 |
US8158385B2 (en) | 2002-10-11 | 2012-04-17 | Chugai Seiyaku Kabushiki Kaisha | Cell death-inducing agent |
US8945543B2 (en) | 2005-06-10 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
US9241994B2 (en) | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5690935A (en) * | 1995-01-13 | 1997-11-25 | Regents Of The University Of Minnesota | Biotherapy of cancer by targeting TP-3/P80 |
US6146628A (en) * | 1995-07-11 | 2000-11-14 | Regents Of The University Of Minnesota And Rutgers | Biotherapeutic agents comprising recombinant PAP and PAP mutants |
AU3916397A (en) * | 1997-08-15 | 1999-03-08 | Regents Of The University Of Minnesota | Biotherapy of cancer by targeting tp-3/p80 |
JP2005533793A (ja) * | 2002-06-17 | 2005-11-10 | パーカー ヒューズ インスティテュート | 抗ウイルス活性を有するアメリカヤマゴボウ抗ウイルス・タンパク質ポリペプチド |
RS20050300A (en) | 2002-10-16 | 2007-08-03 | Euro-Celtique S.A., | Antibodies that bind cell-associated ca 125/0772p and methods of use thereof |
JP5224580B2 (ja) * | 2005-06-10 | 2013-07-03 | 中外製薬株式会社 | sc(Fv)2部位特異的変異体 |
WO2015123654A1 (en) | 2014-02-17 | 2015-08-20 | The Cleveland Clinic Foundation | Amine passivated nanoparticles for cancer treatment and imaging |
US20190192573A1 (en) | 2016-08-19 | 2019-06-27 | Oncoinvent As | Anti-osteosarcoma car-t derived from the antibody oi-3 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2437213A1 (fr) * | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
JPS5616417A (en) * | 1979-07-19 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
JPS5616418A (en) * | 1979-07-20 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
JPS5686121A (en) * | 1979-12-14 | 1981-07-13 | Teijin Ltd | Antitumor proten complex and its preparation |
US4359457A (en) * | 1980-09-30 | 1982-11-16 | Neville Jr David M | Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant |
JPS57106626A (en) * | 1980-12-22 | 1982-07-02 | Teijin Ltd | Cytotoxic protein complex and its preparation |
JPS57106625A (en) * | 1980-12-22 | 1982-07-02 | Teijin Ltd | Cytotoxic protein complex and its preparation |
FR2504010B1 (fr) * | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
EP0067956A1 (de) * | 1981-06-19 | 1982-12-29 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Heterocyclische Verbindungen, Verfahren zu deren Herstellung, Schädlingsbekämpfungsmittel, die diese Verbindungen als Wirkstoffe enthalten, sowie Verwendung solcher Verbindungen und Mittel zur Bekämpfung von Schädlingen |
US4792447A (en) * | 1981-07-23 | 1988-12-20 | Board Of Regents, The University Of Texas System | Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors |
US4916213A (en) * | 1983-02-22 | 1990-04-10 | Xoma Corporation | Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof |
FR2550944B1 (fr) * | 1983-08-23 | 1985-12-06 | Sanofi Sa | Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers |
US4590071A (en) * | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
US4888415A (en) * | 1985-03-04 | 1989-12-19 | Dana-Farber Cancer Institute, Inc. | Gelonin immunotoxin |
US4956453A (en) * | 1985-12-06 | 1990-09-11 | Cetus Corporation | Anti-human ovarian cancer immunotoxins and methods of use thereof |
CA1289880C (en) * | 1985-12-06 | 1991-10-01 | Jeffrey L. Winkelhake | Anti-human ovarian cancer immunotoxins and methods of use thereof |
US4831117A (en) * | 1986-01-03 | 1989-05-16 | Uckun Fatih M | Monoclonal antibody specific for human B-cells |
US4806494A (en) * | 1986-07-24 | 1989-02-21 | The United States Of America As Represented By The Department Of Health & Human Services | Monoclonal antibody against ovarian cancer cells (OVB-3) |
US5541297A (en) * | 1988-04-01 | 1996-07-30 | Immunomedics, Inc. | Therapeutic conjugates of toxins and drugs |
US5167956A (en) * | 1991-02-11 | 1992-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin with in-vivo t cell suppressant activity |
US5690935A (en) * | 1995-01-13 | 1997-11-25 | Regents Of The University Of Minnesota | Biotherapy of cancer by targeting TP-3/P80 |
-
1995
- 1995-01-13 US US08/372,608 patent/US5690935A/en not_active Expired - Lifetime
-
1996
- 1996-01-11 AU AU46524/96A patent/AU4652496A/en not_active Abandoned
- 1996-01-11 EP EP96902074A patent/EP0802799A1/en not_active Ceased
- 1996-01-11 WO PCT/US1996/000104 patent/WO1996021467A1/en not_active Application Discontinuation
- 1996-01-11 JP JP8521737A patent/JPH10508868A/ja not_active Ceased
- 1996-01-11 CA CA002209767A patent/CA2209767A1/en not_active Abandoned
-
1997
- 1997-08-12 US US08/909,976 patent/US6042829A/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8158385B2 (en) | 2002-10-11 | 2012-04-17 | Chugai Seiyaku Kabushiki Kaisha | Cell death-inducing agent |
US8945543B2 (en) | 2005-06-10 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
US9241994B2 (en) | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
US9777066B2 (en) | 2005-06-10 | 2017-10-03 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
WO2008111597A1 (ja) * | 2007-03-12 | 2008-09-18 | Chugai Seiyaku Kabushiki Kaisha | Hlaクラスiを認識する抗体を有効成分として含有する化学療法剤耐性癌治療剤、およびその利用 |
Also Published As
Publication number | Publication date |
---|---|
US6042829A (en) | 2000-03-28 |
WO1996021467A1 (en) | 1996-07-18 |
US5690935A (en) | 1997-11-25 |
EP0802799A1 (en) | 1997-10-29 |
CA2209767A1 (en) | 1996-07-18 |
AU4652496A (en) | 1996-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR0181294B1 (ko) | 생물학적 반응 변경인자용 항체 수송 시스템 | |
AU2016216585B2 (en) | Drug conjugate composition | |
US4664911A (en) | Immunotoxin conjugates employing toxin B chain moieties | |
EP0253202A2 (en) | Novel immunoconjugates and methods for their use in tumor therapy | |
HU208161B (en) | Process for producing cytotoxic active ingredient - antibody conjugates and pharmaceutical compositions | |
US20050100528A1 (en) | Novel antibody delivery system for biological response modifiers | |
JPH10508868A (ja) | TP−3/p80を標的とする癌の生物療法 | |
JP3340127B2 (ja) | 異常増殖性疾患措置のための抗体接合体 | |
DE60105647T2 (de) | Pegylation von linker verbessert die antitumor-aktivität und verringert die toxizität von immunkonjugaten | |
US5151266A (en) | Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies | |
JPS63301832A (ja) | イムノグロブリン結合体 | |
EP0213881B1 (en) | The use of amphipathic molecules for radioimaging and therapy with conjugates of monoclonal or polyclonal antibodies | |
EP0485749A2 (en) | Chemical modification of antibodies for creating of immunoconjugates | |
Rostaing-Capaillon et al. | In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain | |
Rostaing-Capaillon et al. | Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo | |
WO1999008710A1 (en) | BIOTHERAPY OF CANCER BY TARGETING TP-3/p80 | |
Immunotoxins | Parameters Affecting Tumor-specific Delivery of Anti-CD5 | |
JPH0653682B2 (ja) | ヒト免疫グロブリン結合抗腫瘍剤 | |
JPH0611714B2 (ja) | ヒト免疫グロブリン結合抗腫瘍剤 | |
JPH0611713B2 (ja) | ヒト免疫グロブリン結合抗腫瘍剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061114 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070214 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070402 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070627 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070807 |